[HTML][HTML] Update on CSF biomarkers in Parkinson's disease

EH Kwon, S Tennagels, R Gold, K Gerwert, L Beyer… - Biomolecules, 2022 - mdpi.com
Progress in developing disease-modifying therapies in Parkinson's disease (PD) can only
be achieved through reliable objective markers that help to identify subjects at risk. This …

[HTML][HTML] Update on CSF Biomarkers in Parkinson's Disease

EH Kwon, S Tennagels, R Gold, K Gerwert, L Beyer… - …, 2022 - ncbi.nlm.nih.gov
Progress in developing disease-modifying therapies in Parkinson's disease (PD) can only
be achieved through reliable objective markers that help to identify subjects at risk. This …

Update on CSF Biomarkers in Parkinson's Disease

EH Kwon, S Tennagels, R Gold, K Gerwert… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Progress in developing disease-modifying therapies in Parkinson's disease (PD) can only
be achieved through reliable objective markers that help to identify subjects at risk. This …

Update on CSF Biomarkers in Parkinson's Disease.

EH Kwon, S Tennagels, R Gold… - Biomolecules …, 2022 - search.ebscohost.com
Progress in developing disease-modifying therapies in Parkinson's disease (PD) can only
be achieved through reliable objective markers that help to identify subjects at risk. This …

Update on CSF Biomarkers in Parkinson's Disease.

EH Kwon, S Tennagels, R Gold, K Gerwert, L Beyer… - Biomolecules, 2022 - europepmc.org
Progress in developing disease-modifying therapies in Parkinson's disease (PD) can only
be achieved through reliable objective markers that help to identify subjects at risk. This …

Update on CSF Biomarkers in Parkinson's Disease

EH Kwon, S Tennagels, R Gold, K Gerwert, L Beyer… - 2022 - agris.fao.org
Progress in developing disease-modifying therapies in Parkinson's disease (PD) can only
be achieved through reliable objective markers that help to identify subjects at risk. This …

Update on CSF Biomarkers in Parkinson's Disease

EH Kwon, S Tennagels, R Gold, K Gerwert… - …, 2022 - search.proquest.com
Progress in developing disease-modifying therapies in Parkinson's disease (PD) can only
be achieved through reliable objective markers that help to identify subjects at risk. This …

Update on CSF Biomarkers in Parkinson's Disease.

EH Kwon, S Tennagels, R Gold, K Gerwert, L Beyer… - Biomolecules, 2022 - europepmc.org
Progress in developing disease-modifying therapies in Parkinson's disease (PD) can only
be achieved through reliable objective markers that help to identify subjects at risk. This …